Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors (NCT04892823) | Clinical Trial Compass
RecruitingNot Applicable
Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors
United States110 participantsStarted 2021-05-18
Plain-language summary
This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (HCT) survivors and can be used to develop biologically informed interventions to improve quality of life and prolong the healthspan of individuals with accelerated aging.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18 years and older who are competent to give their informed consent.
* Ability to read, speak, and understand English.
* Received a hematopoietic cell transplant within the previous 100 days.
Exclusion Criteria:
* Less then Aged 18 years and older who are competent to give their informed consent.
* Cannot read, speak, and understand English.
* Has not received a hematopoietic cell transplant within the previous 100 days.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The number of participants with gene expression of cellular senescence marker p16.
Timeframe: Day 100 and 1 year post-transplant
Trial details
NCT IDNCT04892823
SponsorMedical College of Wisconsin
Sponsor typeOTHER
Study typeOBSERVATIONAL
Primary completion2027-07-16
Contact for this trial
Medical College of Wisconsin Cancer Center Clinical Trials Office